Jonathan Faison, Seeking Alpha

Jonathan Faison

Seeking Alpha

Contact Jonathan

Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.

Start free trial

  • Unknown
  • Seeking Alpha

Past articles by Jonathan:

Inozyme Pharma: Rare Disease Player Merits Revaluation Higher After POC Data (NASDAQ:INZY)

Inozyme shares are down 58% over the past year. Read why the company's enzyme replacement therapy is an attractive area of drug development. → Read More

Rain Oncology: Multiple Data Catalysts In 2023 For This Precision Oncology Pioneer (RAIN)

Rain Oncology shares have fallen by nearly 40% since 2021 IPO. Read more here. → Read More

AVITA Medical: Experienced CEO Taking The Helm As Expansion Opportunities Await

AVITA Medical shares have fallen by 83% over the past 3 years and are down 13% over the past year. See why I rate RCEL stock a strong buy. → Read More

Fate Therapeutics Stock: iPSC Pioneer A Buy For Long-Term Investors

Fate Therapeutics' shares have fallen by over 80% during the past 12 months. Read more to see why I think FATE stock is a Buy for long-term investors only. → Read More

Avidity Biosciences: Proof-Of-Concept Achieved In DM1 For AOC Platform (NASDAQ:RNA)

Avidity seeks to tackle a fundamental challenge in the RNA space, namely delivery outside the liver via AOC platform technology. See why the stock is a Buy. → Read More

Eton Pharmaceuticals: Alkindi Sprinkle Leads Growth In Orphan Disease Portfolio

Eton Pharmaceuticals' Alkindi Sprinkle is their lead orphan product, addressing a $100M opportunity. Click here to read why ETON stock is a Buy. → Read More

Nkarta (NKTX): A Buy On Pullback With Valuation At Lows

Nkarta is a Buy due to valuation alone, which is likely to rebound next year as key catalysts approach. Read more here. → Read More

ImmunoGen Needs To Make The Most Of Its First-Mover Opportunity (NASDAQ:IMGN)

ImmunoGen's Elahere recently received accelerated approval in FRα-high, platinum-resistant ovarian cancer and sports first-mover advantage. Read why IMGN is a Buy. → Read More

Longboard Pharmaceuticals: Arena Team's Next Act Is Flying Under The Radar

Longboard Pharmaceuticals is a Buy. Key concerns include near term dilution, binary risk as a single drug story and low trading volume. Read my analysis on LBPH. → Read More

UroGen Pharma: Jelmyto Sales Growing Steadily, Concerns Remain (URGN)

UroGen Pharma shares have lost nearly two-thirds of their value over the past 3 years. See why URGN stock is a buy at current levels. → Read More

Axsome Therapeutics: All Eyes On Auvelity Launch

Shares of Axsome Therapeutics have posted a 30% gain so far in 2022. Read more to understand why this stock needs to be watched. → Read More

Y-mAbs Therapeutics: Future Upside Dependent On Reinvigorating Danyelza Sales

Shares have lost 45% in 2022 and are down by 58% since my 2019 article. Conservative peak sales estimate of $200M vs, current enterprise value of $260M. → Read More

Scholar Rock: OLE Data In SMA Coupled With New CEO Make It A Buy

Scholar Rock shares have lost over 20% of their value during the past 3 years and are down 70% so far in 2022. Click here to find out why SRRK is a Buy. → Read More

Immunovant Stock: Capitalizing On Fast Growing FcRn Space With Novel Asset (NASDAQ:IMVT)

Shares have lost roughly half their value since arriving on the Nasdaq in late 2019 via SPAC. See why IMVT is a Buy and I suggest initiating a pilot position in the near term. → Read More

ORIC Pharmaceuticals (ORIC) Stock: Poster Child For The Current Downturn In Biotech

ORIC is a speculative Buy. Key risks include disappointing data for phase 1 readouts 1H23, delays in the clinic and heavy competition in certain areas. Read more. → Read More

IDEAYA Biosciences: Prospects Rebound With Updated Uveal Melanoma Data (NASDAQ:IDYA)

IDEAYA Biosciences stock has posted a 40% loss over the past 12 months. But click here to know the reasons why IDYA is still a Buy. → Read More

Arcutis Biotherapeutics: Keeping A Close Eye On Launch Metrics For Zoryve (NASDAQ:ARQT)

Arcutis Biotherapeutics' shares are down 15% year to date. Read more to see why ARQT stock is a buy for long-term investors. → Read More

Cullinan Oncology: Modality-Agnostic Approach To Yield Fruit In Coming Years (NASDAQ:CGEM)

Patient investors with a multi-year timeframe should consider Cullinan Oncology. Click here for a full investment analysis of CGEM stock. → Read More

Aadi Bioscience: Taking mTOR Inhibition To The Next Level (NASDAQ:AADI)

Aadi Bioscience shares lost half their value since reverse merger with Aerpio Pharmaceuticals. Click here to read why AADI stock is a Buy in my view. → Read More

Aldeyra Therapeutics: Dry Eye Is Just The Beginning For Novel MOA (NASDAQ:ALDX)

At the current valuation, the market is more optimistic about Aldeyra's approach to RASP and prospects for lead program reproxalap. Click here to see why ALDX is a Buy. → Read More